• 1
    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, Version 2.0, vol. 2005. IARC CancerBase No. 5. Lyon: IARC Press, 2004.
  • 2
    Bosch FX, Lorincz A, Munoz N, Meijer C, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 24465.
  • 3
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 4238.
  • 4
    Moscicki AB, Shiboski S, Boroering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller BA, Stone J, Hanson E, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132: 27784.
  • 5
    Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 136571.
  • 6
    Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 205.
  • 7
    Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341: 16338.
  • 8
    Schlecht NF, Kulaga S, Robitaille J. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286: 310614.
  • 9
    Munoz N, Bosch FX, deSanjose S, Snijders PJF, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51857.
  • 10
    Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Kurman RJ, Manos MM. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169: 23540.
  • 11
    Franco E, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan T. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 141523.
  • 12
    Ahdieh L, Klein RS, Burk RD, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184: 68290.
  • 13
    Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 1015.
  • 14
    Barbosa MS, Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989; 4: 152932.
  • 15
    Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology 1991; 181: 3747.
  • 16
    Liaw KL, Hildesheim A, Burk R, Gravitt PE, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 815.
  • 17
    Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, Abrahamsen M, Inserra P, Olvera S, Hatch K. Incidence, prevalence, and clearance of type specific human papillomavirus: The young women's health study. J Infect Dis 2002; 186: 4629.
  • 18
    Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC,Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 13439.
  • 19
    Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 18316.
  • 20
    Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee F, Franco EL. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12: 48590.
  • 21
    Molano M, van den Brule AJC, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer C, Munoz N, Franceschi S. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 48694.
  • 22
    Massad LS, Ahdieh L, Benning L, Minkoff H, Greenblatt RM, Watts H, Miotti P, Anastos K, Moxley M, Muderspach LI, Melnick S. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2001; 27: 43242.
  • 23
    Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson DJ, Anderson J, Shah KV. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188: 12836.
  • 24
    Smith DK, Warren DL, Vlahov D, Schuman P, Stein MD, Greenberg BL, Holmberg SD. Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol 1997; 146: 45969.
  • 25
    Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbid Mortal Wkly Rep. 1987; 36: 1S15S.
  • 26
    Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD, PEG Group, ALTS Group. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 14750.
  • 27
    Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129: 12537.
  • 28
    Greenland S, Rothman KJ. Approximate statistics: the likelihood-ratio method. In: RothmanKJ, GreenlandS, eds. Modern epidemiology, 2nd edn. Philadelphia, PA: Lippincott Williams and Wilkins, 1998. 21820.
  • 29
    Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 10748.
  • 30
    Allison PD. Repeated events. In: Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute Inc, 1995. 23647.
  • 31
    Allison PD. Cox models with nonproportional hazards. In: Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995. 1547.
  • 32
    Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA, Shah K. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151: 11481157.
  • 33
    Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall CB, Fazzari M, Cu-Uvin S, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95: 106271.
  • 34
    Schiffman M, Castle PE. Human papillomavirus—epidemiology and public health. ArchPathol Lab Med 2003; 127: 93034.
  • 35
    Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 35761.